Showing 3171-3180 of 3314 results for "".
- Cultivating 4-D Tissues: The Self-Curving Corneahttps://modernod.com/news/cultivating-4-d-tissues-the-self-curving-cornea/2476176/Scientists at Newcastle University have developed a biological system which lets cells form a desired shape by moulding their surrounding material—in the first instance creating a self-curving cornea. In the research, a flat circle of gel containing corneal stromal cells (stem
- Allergan, Mohawk Tribe Ask for Supreme Court Review of Scrutinized Patent Casehttps://modernod.com/news/allergan-mohawk-tribe-ask-for-supreme-court-review-of-scrutinized-patent-case/2476180/Allergan and the St. Regis Mohawk Tribe aim to continue their legal battle in defense of a controversial patent agreement struck a little over a year ago, appealing last week to the Supreme Court to review a federal appeals court decision which had undermined the deal’s main r
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- US House Oversight Committee Launches Investigation into Prescription Drug Pricinghttps://modernod.com/news/us-house-oversight-committee-launches-investigation-into-prescription-drug-pricing/2476191/The US House of Representatives’ Oversight Committee on Monday announced a probe into a dozen pharmaceutical companies regarding drug pricing. In the investigation, Representative and committee chairman Elijah Cummings sent letters to AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson
- Take Diabetes Into Consideration When Assessing for Glaucomahttps://modernod.com/news/take-diabetes-into-consideration-when-assessing-for-glaucoma/2476193/Diabetes and hyperglycemia are associated with thicker central corneal thickness (CCT), which could lead to overestimation of intraocular pressure when assessing patients for glaucoma, new research suggests, as reported by Medscape.
- US Democratic Lawmakers Introduce Bills Targeting Drug Pricinghttps://modernod.com/news/us-democratic-lawmakers-introduce-bills-targeting-drug-pricing/2476197/US lawmakers including Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday seeking to reduce prescription drug prices. “The United States pays by far the highest prices in the world for prescription drugs,” Sen. Sanders commented, adding “
- In Memoriam: Jack J. Kanski, FRCS, FRCOphthhttps://modernod.com/news/in-memoriam-jack-j-kanski-frcs-frcophth/2476199/World-renowned ophthalmologist Jacek Jerzy Kanski (better known as Jack J. Kanski, FRCS, FRCOphth) died on January 5, 2019. Few authors have left behind so vast a legacy. His books have enabled tens of thousands of ophthalmologists around the world to pass their examinations and have served as re
- Riata Capital’s Acuity Eyecare Group Completes Acquisitions in Colorado and Nebraskahttps://modernod.com/news/riata-capitals-acuity-eyecare-group-completes-acquisitions-in-colorado-and-nebraska/2476208/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of leading North American eyecare groups and optometry practices, has acquired two new regional eyecare groups, totaling 18 locations: ABBA Eye Care, based in Colorado Springs, Colora
- Kala Pharmaceuticals Announces the Launch of Inveltyshttps://modernod.com/news/kala-pharmaceuticals-announces-the-launch-of-inveltys-and-the-hiring-of-a-specialty-ophthalmology-sales-organization/2476217/Kala Pharmaceuticals announced the launch of Inveltys (loteprednol etabonate ophthalmic suspension) 1%, the first and only twice-daily ocular corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Kala also announced the hiring of the specialty
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana